drugset
drugset / Trial / NCT03492437

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

NCT03492437 ↗

Phase 1 Completed 20 enrolled Merck KGaA, Darmstadt, Germany
NaCrossoverOpen-labelOther

Summary

This study investigated the effect of Tepotinib on the pharmacokinetics (PK) of the p-glycoprotein (P-gp) probe substrate Dabigatran etexilate.

Timeline

Start
2018-05-17
Primary completion
2018-08-27
Completion
2018-08-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 75 mg Oral
Subject Tepotinib Small molecule 500 mg Oral

Indications

No indication recorded.